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Abstract
Background: Among the non-invasive screening methods for the identification of fetal aneuploidy, NIPT (non-invasive
prenatal testing) shows the highest sensitivity and specificity in high-risk pregnancies. Due to the low false positive rate
of NIPT, it is assumed that the implementation of NIPT as a primary screening method may reduce the number of
invasive fetal tests and result in a similar or lowered cost in the overall detection of Down syndrome. However, most
previous studies are based on theoretical economic analysis. This study aims to determine the cost effectiveness of
various prenatal test strategies, including NIPT, in real clinical settings in both low risk and high risk pregnancies.
Methods/design: In this prospective observational study, women (< 24 weeks) with singleton or twin pregnancies will
be enrolled in 12 different healthcare institutions. The participants will be grouped based on the risks of fetal
chromosomal abnormalities and will be counseled on the various screening or diagnostic methods, including NIPT,
according to the aneuploidy risk. The final decision on screening or diagnostic methods will be made by patients after
counseling. Questionnaires regarding factors affecting the decision on prenatal test will be answered by the
participants and physicians. The economic analysis on final total costs will be compared according to the various
prenatal test strategies.
Discussion: The results of present study are expected to have a significant impact on national policies in determining
Korean prenatal screening test strategies and to help in developing novel and effective prenatal screening tests in the
future.
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Background
Aneuploidy is defined as a numerical abnormality of
chromosomes and is reported to have an incidence of 1
out of 160 live births [1]. Prenatal diagnosis of aneu-
ploidy is crucial, since it is associated with an increased
perinatal morbidity and mortality. In addition, the pres-
ence of fetal aneuploidy can affect decision making in
fetal treatment, screening, and method of delivery.
Several strategies are currently available for the identifi-
cation of fetal aneuploidy [2]. Invasive test includes chori-
onic villi sampling, amniocentesis, and cordocentesis, and
is usually indicated for high-risk pregnant women in order
to diagnose aneuploidy. The procedure-related risk of this
invasive test amounts to 1/300–1/500 within two weeks
[3, 4], which restricts this tests from being universally used
in low-risk pregnancies. In addition, such an invasive test
requires highly trained professionals for the diagnostic
procedure. The conventional non-invasive screening tests
include maternal serum screening with biochemical
markers or ultrasound examination, such as the measure-
ment of fetal nuchal translucency (NT). Among the
non-invasive screening methods, triple test and quad test
have the accuracy rate of 61–70% and 74–81%, respectively
in diagnosing Down syndrome, with the false positive rate
of 5% [2, 5]. At 12-week pregnancy, using maternal blood
markers, namely, PAPP-A and free beta-hCG, has only 79–
87% accuracy rate, with 5% false positive rate [5]. Recently,
integrated test involving maternal serum test combined
with sonographic results through the first to mid-trimester
pregnancy has been introduced, with limited detection rate
of 94–96% [5].
Another method introduced in the USA in 2011 and
now widely used in 60 different countries is analyzing
fetal cell-free DNA in maternal blood sample which is
called as NIPT (non-invasive prenatal testing). In recent
guidelines, the NIPT is indicated mainly in high-risk
pregnant women [6] and shows the highest sensitivity
(> 99%) with low false positive rate (<= 0.15%) for the
detection of Down syndrome in high-risk pregnancies
[7–12].
Due to this low false positive rate, it is assumed that
the implementation of NIPT as a screening method may
reduce the number of invasive fetal tests. In the study of
Larion et al., NIPT’s high detection rate reduces undue
invasive prenatal screening tests [13], therefore reducing
fetal mortality rate caused by conventional invasive tests.
In terms of cost effectiveness, the decreased number
of invasive tests may result in a similar or lowered cost
in the overall detection of Down syndrome, as compared
to other screening or diagnostic methods. NIPT is ex-
pensive, with the associated cost ranging from $795 to
$2900 depending on the country; However, the high ac-
curacy rate of NIPT has a value in reducing invasive pre-
natal tests [1, 13]. These conflicting points (high cost
and a value in reduction of invasive test) raise the ques-
tions about the cost effectiveness of NIPT in both
high-risk and low-risk pregnant women. However, the
advantage may be more critical in high-risk pregnancies,
although clinical application of NIPT to all pregnant
women may not be economically practical.
In the literature, there have been several studies on the
cost effectiveness of NIPT (Table 1). Most studies are
based on theoretical economic analysis, especially in
high-risk pregnancies [14–17]. In England, prospective ob-
servational study has been conducted and showed that
NIPT decreased invasive tests with same detection rate
[18]. This England study was the first study on the effect-
iveness of NIPT in real world situation than in theoretical
model, but this study did not included low risk women
(included women with aneuploidy risk of at least 1/1000).
To determine this issue, we aimed to evaluate the cost
effectiveness of different prenatal test strategies for the
identification of fetal aneuploidy, including NIPT, in real
clinical setting in both low risk and high risk pregnancies.
Methods/design
Study design
This is a multi-center prospective observational study.
Fig. 1 depicts the study design with a clinical pathway.
The participants will be counseled on various screening
or diagnostic methods, based on risks of fetal chro-
mosomal abnormalities. The final decision on screening
or diagnostic methods will be made by patients after
counseling.
Population and recruitment
Singleton or twin pregnant women (< 24 weeks of ges-
tation) who are candidates for the identification of fetal
aneuploidy will be enrolled in 12 different healthcare
institutions between June 2016 and October 2018. The
participating hospitals include teaching hospitals in
urban areas.
Sample size
A prior sample size calculation was performed to deter-
mine how many participants would be needed to esti-
mate sensitivity of the NIPT. We estimated that the
prevalence of Down syndrome would be 3% and the pro-
portion of NIPT tests among prenatal screening tests
would be 15% in high-risk pregnancies from the partici-
pating health centers, in which the frequency of high
risk-pregnancies was estimated to amount to 33% (1/3)
of the total number of pregnancies. With the predeter-
mined sensitivity of 99% which is ascertained by previ-
ous studies and marginal error of 0.07, 259 women who
choose NIPT among prenatal screening tests and a total
of 5174 pregnant women would be required. Accounting
for the dropout rate, we estimated the minimum sample
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size as 6000 participants. The 12 participating health
care centers had a total of about 17,000 births and about
11,000 maternal serum screenings in one year.
Inclusion criteria
Inclusion criteria are as follows: (1) singleton/twin preg-
nant women who present at participating institutions be-
fore 24 weeks gestation and (2) candidates for the
identification of fetal aneuploidy; (3) 18 years of age or
older; (4) Asian ethnicity; (5) ability to read in and speak
Korean; (6) provided written informed consent.
Exclusion criteria
Exclusion criteria are as follows: (1) higher-order multi-
fetal pregnancy; (2) women who visit after 24 weeks; (3)
younger than 18 years of age; (4) ethnic background
other than Asian.
Classification of fetal aneuploidy risk
The participants will be grouped based on the risks of
fetal chromosomal abnormalities.
Group 1: low risk (no specific risk).
Group 2: advanced maternal age, 35 years or older at
the time of delivery.
Group 3: Positive result in maternal serum biochem-
ical test.
Group 4: Abnormal ultrasonographic findings associ-
ated with increased risk of aneuploidy.
4–1: increased nuchal translucency (NT).
4–2: presence of soft marker – ultrasonographic find-
ings that are not major anomalies, but indicative of in-
creased risks of chromosomal anomalies (brachycephaly
or shortened frontal lobe, clinodactyly, echogenic bowel,
flat facies, echogenic intracardiac foci, nasal bone ab-
sence or hypoplasia, nuchal fold thickening, pyelectasia,
sandal gap between the 1st and 2nd toes, shortened ear
length, single transverse palmar crease, single umbilical
artery, short long bone, or widened iliac angle).
4–3: major anomaly.
Group 5: prior pregnancy history.
5–1: chromosomal abnormality.
5–1-a: trisomy 13, 18, or 21.
5–1-b: other chromosomal abnormality.
(ex. Tuner syndrome, Robertsonian translocations, etc.)
5–2: congenital anomaly.
Group 6: Maternal or paternal chromosomal
abnormality.
6–1: increased risk of trisomy 21, 13.
6–2: other chromosomal abnormality.
Group 7: Positive result in NIPT.
Group 8: Genetic counselling due to abnormal results
of invasive test.
Counseling and decision on prenatal test
The participants will be counseled on the various pre-
natal tests, including maternal serum screening, NIPT,
and invasive prenatal test. The available maternal serum
screening tests in Korea include dual test, triple test,
quad test, integrated test, sequential test, and contingent
Table 1 Several studies for determining cost effectiveness of NIPT
Study Method of
analysis
Study population Prenatal tests strategies Result




General population Current practice and NIPT Most cost-effective for women
over 40 years of age










NIPT is the most cost-effective
after primary screen method at
age 40 years and older
Genevieve Fairbrother
et al., 2015 [16]
Decision-analytic
model
General population NIPT, first trimester combined screening
(FTS)
NIPT is more economical,
below $453




General population Contingent NIPT,
conventional maternal serum
screening (MSS), universal NIPT
Universal NIPT is more
cost-effective from a
societal perspective view





risk for Down syndrome




NIPT as a contingent test within
DSS program can make more
effective outcome of prenatal care
Current study Real clinical
setting
General population Maternal serum test (dual test,
triple test, quad test,
integrated test, sequential test,
and contingent test),
invasive test (CVS, amniocentesis,
cordocentesis), NIPT
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test. Available diagnostic tests include chorionic villi
sampling, amniocentesis, and cordocentesis.
For women classified as high-risk group on maternal
serum test (group 3) will be recommended to NIPT or
invasive test. And invasive test will be recommended for
women with positive result in NIPT (groups 7), or with
markedly increased NT or with major anomaly (groups
4–1, 4–3). The following tests are the firstly recom-
mended tests by a physician, based on the classification
of fetal aneuploidy risk.
Group 1: Maternal serum screening test, NIPT.
Group 2: Maternal serum screening test, NIPT, Inva-
sive test.
Group 3: NIPT, Invasive test.
Group 4–1, 4–3: Invasive test.
Group 4–2: Maternal serum screening test, NIPT, in-
vasive test.
Group 5–1: NIPT, Invasive test.
Group 5–2: Maternal serum screening test, NIPT, in-
vasive test.
Group 6–1: NIPT, Invasive test.
Group 6–2: Invasive test.
Group 7: Invasive test.
However, the final decision on screening or diagnostic
methods will be made by patients after counseling, in
the awareness of their costs.
Maternal serum screening test
Maternal serum screening test includes double marker
(PAPP-A and free beta-hCG), Triple marker (AFP, total
hCG, uE3), Quad marker (AFP, total hCG, uE3, Inhibin
A), integrated test, sequential test, and contingent test. In
the integrated test, the risk will be tested by the
combination of the first trimester markers (serum
PAPP-A and NT in ultrasound) and the second trimester
markers (AFP, total hCG, uE3, Inhibin A). For sequential
test, risk will be calculated separately in the first trimester
(free-hCG, PAPP-A and NT) and in the second trimester
(quad test). Each test will be performed in individual hos-
pitals or by commercial services.
Invasive test (Cytogenic test)
Cytogenic analysis consists of invasive tests, such as
chorionic villous sampling, amniocentesis, and cordo-
centesis. The final results of these tests will be confirmed
by conventional karyotyping. After two weeks, the com-
plications associated with procedures will be determined
by the presence of preterm premature rupture of mem-
branes, preterm labor, fetal death in utero, and other
complications.
Fetal ultrasound test
In the first trimester, fetal nuchal translucency will be
measured according to the nuchal translucency meas-
urement protocol by Fetal Medicine Foundation. In the
2nd trimester (usually after 18 weeks of gestation), level
II ultrasound will be performed for the detection of fetal
anomalies.
NIPT
The level of risk on Down syndrome, Edward syndrome,
Patau syndrome, sex chromosomal abnormality will be
analyzed in pregnant women who choose NIPT. The
NIPT will be performed by several commercially avail-
able tests in Korea.
Fig. 1 Protocol diagram
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Investigation of the factors affecting the decision
Factors affecting the decision on the prenatal test will be
assessed with the questionnaire answered by the partici-
pants (Additional file 1) and physicians (Additional file
2). The patients' questionnaire will be developed with
the modification of that used in the study previously
published by Lewis C. et al. (PMID: 24433394) In
addition, participants will be asked about demographic
information, past medical history, and obstetrical history,
including history of major anomaly, genetic disorder, or
aneuploidy in prior pregnancy.
Delivery outcome
The data on the result of prenatal tests and pregnancy/
neonatal outcomes will be gathered in a subsequent re-
view of medical records. The information on gestational
age at delivery, neonatal birth weights, the presence of
congenital anomalies, and postnatal cytogenetic study (if
performed) will be collected.
The cost-effective analysis
A cost-utility analysis comparing various prenatal test
strategies will be performed from the societal perspective.
Transition probabilities and cost data will be estimated
from the clinical data collected from 12 participating
health centers. Contingent valuation scenarios will be used
to solicit utility data for major health states, such as aneu-
ploidy and miscarriage among the pregnant women who
have agreed to participate in the study. The incremental
cost effectiveness ratio (ICER) analysis will be used to
identify the most cost-effective strategy.
Discussion
In this study, we will try to find out which method is
more cost-effective for detection of fetal aneuploidy, in-
cluding NIPT.
NIPT is expensive ranging from $795 to 2900 depend-
ing on countries in the literature, and the NIPT cost in
Korea is between 550,000 and 800,000 KRW. However,
the high accuracy rate of NIPT has a value in reducing
invasive prenatal tests [1, 13]. These conflicting points
(high cost and a value in reduction of invasive test)
raised the questions on the cost-effectiveness of NIPT in
both high-risk and low-risk pregnant women. In the lit-
erature, there have been several studies on the
cost-effectiveness of NIPT (Table 1). The NIPT has been
shown to be cost-effective, especially in high risk patients.
However, the cost-effectiveness of NIPT in low risk
women has not been well determined. In addition, these
previous studies are mostly based on theoretical economic
analysis and clinical data in a ‘real-world situation’ has not
been well evaluated. Lastly, the cost-effectiveness analysis
in Korean population seems to be important, because the
mean age of Korean pregnant women was higher than
other countries (such as USA and England) and old age it-
self can be a high risk factor [19].
To our knowledge, this study will be the first study which
evaluated the cost effectiveness of NIPT in low risk
Table 2 Subsequent studies using the data derived from our study
Cost-effectiveness study Cost-effectiveness of various prenatal tests in real clinical setting
- In both low risk and high risk pregnancy
- In both singleton and twin pregnancy
Factors affecting the
decision
1) Questionnaire Study: factors affecting the decision on prenatal test by both participants, husbands and attending
physicians in real clinical setting
2) Clinical factors affecting the decision in real clinical setting
- In both low risk and high risk pregnancy
- In both singleton and twin pregnancy
NIPT 1) Clinical aspect: Introduction of NIPT and its effects on selection of prenatal test including invasive diagnostic tests
- In both low risk and high risk pregnancy
- In both singleton and twin pregnancy
2) Diagnostic aspect: the diagnostic accuracy and no-call reports of NIPT
- In both low risk and high risk pregnancy
- In both singleton and twin pregnancy
3) The usefulness of NIPT in structural malformation or in increased nuchal translucency
4) The risk of major structural malformation according to the results of various prenatal tests
Maternal serum
screening
Evaluation of adverse pregnancy outcomes according to the maternal serum screening test
- In both low risk and high risk pregnancy
- In both singleton and twin pregnancy
Invasive test study 1) Complication rate including abortion in invasive prenatal tests in Korean clinical settings
- In both low risk and high risk pregnancy
- In both singleton and twin pregnancy
2) Change in abortion rate after the introduction of NIPT
Guidelines 1) Development of guidelines for prenatal screening test
2) Development of guidelines for prenatal diagnostic test
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pregnancies in reality. In addition, this will be the first study
determining the impact of NIPT in twin pregnancies.
The results of this study are expected to have a signifi-
cant impact on improving national health, and related
policies (Table 2). First, on national health level, prenatal
screening guidelines would reduce unnecessary invasive
tests and result related abortion. Secondly, prenatal
screening costs would be reduced. Third, more effective
government policies would be made for prenatal care
and gathering evidence for improving low birth rates. Fi-
nally, this would be basis of effective prenatal screening.
Additional files
Additional file 1: Patients Questionnaire: Korean version and Patients
Quesionnaire: English version. (ZIP 524 kb)
Additional file 2: Physicians Questionnaire: Korean version and
Physicians Questionnaire: English version. (ZIP 536 kb)
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